Phase II studies in vadadustat and daprodustat have not demonstrated any significant change in VEGF, and in a VEGF-sensitive model of spontaneous breast cancer, roxadustat was not associated with tumor initiation, progression, or metastases [68, 72]. The gene discussed is VEGFA; the disease is breast cancer.